CO-OP) for children aged 8-12 diagnosed with co-occurring DCD and high-functioning ASD. The market for pediatric neurodevelopmental therapies is expanding, particularly as awareness of co-morbid conditions like DCD and ASD increases. The trial's innovative approach could position it favorably against existing therapies that primarily focus on social and communication skills in ASD, potentially leading to new clinical practices that address motor skills. Companies focusing on neurodevelopmental disorders may find strategic partnerships or investment opportunities in this area, especially if the trial demonstrates significant improvements in motor function and associated neuroplastic changes.